Apogenix’ Asunercept Demonstrates Efficacy in Phase II Trial for the Treatment of Hospitalized COVID-19 Patients (English only)
- Clinical efficacy demonstrated for all asunercept dose groups
- Statistically significant faster clinical recovery for combined treatment groups compared to control group
- Excellent safety profile of asunercept confirmed
- Pivotal phase III study initiated
Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that asunercept showed statistically significant benefits for hospitalized COVID-19 patients in the ASUNCTIS trial. The open-label multi-center phase II trial investigated efficacy and safety of asunercept in 435 patients with moderate to severe COVID-19 disease. COVID-19 patients were randomized equally into four study arms, receiving 25, 100, or 400 mg asunercept (once weekly, i.v.) on top of standard of care (SOC), respectively, or SOC alone.